Last edition
News about "Clostridioides difficile infection "
Acurx Pharmaceuticals Secures FDA Conditional Acceptance of Cifbezy Name for Ibezapolstat
Acurx Pharmaceuticals has secured FDA conditional acceptance of Cifbezy as the proposed brand name for ibezapolstat and received USPTO trademark allowance, marking key preparatory milestones ahead of planned international Phase 3 development for C. difficile infection.
Clostridioides Difficile Infection | 18/08/2026 | By News Bureau
Tillotts Pharma AG Celebrates 15 Years Anniversary as Part of Japanese Zeria Group
This commitment has also led to Tillotts in-licensing the product Dificlir™ for the treatment of Clostridioides difficile infection (CDI) in 2020, a potentially life-threatening disease.
Clostridioides Difficile Infection | 14/02/2025 | By Aishwarya | 480
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy